| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IVX Overview
Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia.
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.014 |
| 52 Week High | AU$0.008 |
| 52 Week Low | AU$0.02 |
| Beta | 1.85 |
| 1 Month Change | -6.67% |
| 3 Month Change | 0% |
| 1 Year Change | 27.27% |
| 3 Year Change | -44.00% |
| 5 Year Change | 366.67% |
| Change since IPO | -96.46% |
Recent News & Updates
Estimating The Intrinsic Value Of Invion Limited (ASX:IVX)
Does the March share price for Invion Limited ( ASX:IVX ) reflect what it's really worth? Today, we will estimate the...
We Think Invion (ASX:IVX) Can Easily Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Shareholder Returns
| IVX | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 7.7% | 1.8% | 1.7% |
| 1Y | 27.3% | 5.8% | 20.2% |
Return vs Industry: IVX exceeded the Australian Pharmaceuticals industry which returned 5.8% over the past year.
Return vs Market: IVX exceeded the Australian Market which returned 20.2% over the past year.
Price Volatility
| IVX volatility | |
|---|---|
| IVX Beta | 1.85 |
| Industry Beta | 1.3 |
| Market Beta | 1 |
Stable Share Price: IVX is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: IVX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Thian Chew | https://www.inviongroup.com |
Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a chlorophyll-based photosensitizer to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion’s IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer.
Invion Fundamentals Summary
| IVX fundamental statistics | |
|---|---|
| Market Cap | AU$76.24m |
| Earnings (TTM) | -AU$1.48m |
| Revenue (TTM) | AU$2.33m |
35.9x
P/S Ratio-56.0x
P/E RatioIs IVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IVX income statement (TTM) | |
|---|---|
| Revenue | AU$2.33m |
| Cost of Revenue | AU$1.52m |
| Gross Profit | AU$810.51k |
| Expenses | AU$2.29m |
| Earnings | -AU$1.48m |
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00025 |
| Gross Margin | 34.79% |
| Net Profit Margin | -63.65% |
| Debt/Equity Ratio | 0.0% |
How did IVX perform over the long term?
See historical performance and comparisonValuation
Is Invion undervalued compared to its fair value and its price relative to the market?
37.0%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IVX (A$0.01) is trading below our estimate of fair value (A$0.02)
Significantly Below Fair Value: IVX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: IVX is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.
PE vs Market: IVX is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IVX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IVX is overvalued based on its PB Ratio (17.3x) compared to the AU Pharmaceuticals industry average (3.5x).
Future Growth
How is Invion forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
67.4%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Invion has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Invion performed over the past 5 years?
12.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IVX is currently unprofitable.
Growing Profit Margin: IVX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IVX is unprofitable, but has reduced losses over the past 5 years at a rate of 12.9% per year.
Accelerating Growth: Unable to compare IVX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IVX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).
Return on Equity
High ROE: IVX has a negative Return on Equity (-30.96%), as it is currently unprofitable.
Financial Health
How is Invion's financial position?
Financial Position Analysis
Short Term Liabilities: IVX's short term assets (A$1.1M) exceed its short term liabilities (A$851.5K).
Long Term Liabilities: IVX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: IVX is debt free.
Reducing Debt: IVX has no debt compared to 5 years ago when its debt to equity ratio was 21.9%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable IVX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: IVX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 58% per year.
Dividend
What is Invion current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IVX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IVX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IVX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IVX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IVX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.8yrs
Average board tenure
CEO
Thian Chew
1
Tenure
AU$367,825
Compensation
Mr. Thian Chew has been Executive Chairman and Chief Executive Officer at Invion Limited since November 1, 2020 and also served as Interim Chief Executive Officer since October 31, 2020 until November 1, 2...
CEO Compensation Analysis
Compensation vs Market: Thian's total compensation ($USD275.01K) is about average for companies of similar size in the Australian market ($USD302.06K).
Compensation vs Earnings: Thian's compensation has increased whilst the company is unprofitable.
Board Members
Experienced Board: IVX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: IVX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.6%.
Top Shareholders
Company Information
Invion Limited's employee growth, exchange listings and data sources
Key Information
- Name: Invion Limited
- Ticker: IVX
- Exchange: ASX
- Founded: 2000
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$76.243m
- Shares outstanding: 5.86b
- Website: https://www.inviongroup.com
Number of Employees
Location
- Invion Limited
- 100 Albert Road
- Level 4
- Melbourne
- Victoria
- 3205
- Australia
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/10/20 07:04 |
| End of Day Share Price | 2021/10/20 00:00 |
| Earnings | 2021/06/30 |
| Annual Earnings | 2021/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.